Document is current
Any future updates will be listed below
-
Authors
Burrell, Rebecca A.
Kumar, Sanjeev
Provenzano, Elena
Pike, Cleopatra
Dayimu, Alimu https://orcid.org/0000-0001-9998-7463
McIntosh, Stuart A. https://orcid.org/0000-0002-4123-9611
Pitsinis, Vassilis
King, Polly
Elsberger, Beatrix https://orcid.org/0000-0002-2864-5789
Govindarajulu, Sasi
Satherley, Lucy
Hadad, Sirwan
Schmid, Peter
Agrawal, Amit https://orcid.org/0000-0002-3144-0493
Akpuluma, Bodiere
Bell, Steven https://orcid.org/0000-0001-6774-3149
Benson, John R.
Caldas, Carlos https://orcid.org/0000-0003-3547-1489
Cheeseman, Danya
Chernukhin, Igor
Forouhi, Parto
Gulsen, Tulay
Kleidi, Eleftheria
Pinilla, Karen https://orcid.org/0000-0002-2723-0805
Qian, Wendi https://orcid.org/0000-0002-4238-3471
Abraham, Jean E. https://orcid.org/0000-0003-0688-4807
Carroll, Jason S.
Baird, Richard D. https://orcid.org/0000-0001-7071-6483
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 30 October 2025
First Online: 5 January 2026
Competing interests
: R.D.B. reports honoraria (paid to institution) from advisory boards for AstraZeneca, Genentech, Molecular Partners, Novartis, Roche and Shionogi and research funding from AstraZeneca, Boehringer-Ingelheim, Carrick Therapeutics, Daiichi Sankyo, G1 Therapeutics, Genentech, Molecular Partners, Novartis, Roche and Shionogi. E.P. reports honoraria from Roche, AstraZeneca and Exact Sciences and research funding from IBEX Analytics. S.M. reports speaker honoraria from Merck Sharp and Dohme, Roche, BD, Veracyte and Exact Sciences, membership on advisory boards for Roche, Lilly, Novartis and Merck Sharp and Dohme and conference travel and support from Roche, Lilly, Novartis and Merck Sharp and Dohme. J.E.A. reports speaker honoraria from AstraZeneca, Eisai and Pfizer and membership on advisory boards for AstraZeneca. The remaining authors declare no competing interests.
